A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects
Open Access
- 16 October 2011
- journal article
- review article
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2011, 1-6
Abstract
Recently identified interleukin-28 and -29 belong to a novel type III interferon (IFN) family, which could have distinct biological properties from type I and II IFNs. Type I IFNs, IFN-α/β, have been clinically applied for treating a certain kind of malignancies for over 30 years, but a wide range of the adverse effects hampered the further clinical applications. Type III IFNs, IFN-λs, have similar signaling pathways as IFN-α/βand inhibits proliferation of tumor cells through cell cycle arrest or apoptosis. Restricted patterns of type III IFN receptor expression in contrast to ubiquitously expressed IFN-α/βreceptors suggest that type III IFNs have limited cytotoxicity to normal cells and can be a possible anticancer agent. In this paper, we summarize the current knowledge on the IFN-λs-mediated tumor cell death and discuss the functional difference between type I and III IFNs.Keywords
This publication has 31 references indexed in Scilit:
- Interleukin-29 Binds to Melanoma Cells Inducing Jak-STAT Signal Transduction and ApoptosisMolecular Cancer Therapeutics, 2010
- Interferons α and γ induce p53-dependent and p53-independent apoptosis, respectivelyOncogene, 2004
- Interferons, interferon‐like cytokines, and their receptorsImmunological Reviews, 2004
- Interferon type I gene expression in chronic hepatitis CLaboratory Investigation, 2004
- Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-λ1Journal of Biological Chemistry, 2004
- The Class II cytokine receptor (CRF2) family: overview and patterns of receptor–ligand interactionsCytokine & Growth Factor Reviews, 2004
- Comparative genomic analysis reveals independent expansion of a lineage-specific gene family in vertebrates: The class II cytokine receptors and their ligands in mammals and fishBMC Genomics, 2003
- Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defenceNature, 2003
- IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complexNature Immunology, 2002
- Combined regimen of cisplatin, doxorubicin, and ?-2b interferon in the treatment of advanced malignant pleural mesotheliomaCancer, 2001